Yongchun Zhou

Yongchun Zhou

Auto-generated profile, based on publicly available information

Yongchun Zhou

Molecular Diagnostics Center, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming, Yunnan, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYongchun Zhou
Yongchun Zhou
YYYanlong Yang
Yanlong Yang
CYChenggang Yang
Chenggang Yang
YCYunlan Chen
Yunlan Chen
CYChangshao Yang
Changshao Yang
YHYun Chao Huang
Yun Chao Huang
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China

9 May 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GZGuangqiang Zhao
Guangqiang Zhao
ZWZhengxi Wang
Zhengxi Wang
YHYun Chao Huang
Yun Chao Huang
LYLianhua Ye
Lianhua Ye
KYKaiyun Yang
Kaiyun Yang
YZYujie Zeng
Yujie Zeng

14 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YMYuhui Ma
Yuhui Ma
QLQuan Li
Quan Li
YDYaxi Du
Yaxi Du
JCJingjing Cai
Jingjing Cai
WCWanlin Chen
Wanlin Chen
YZYongchun Zhou
Yongchun Zhou
This study was designed to investigate the impact of blood tumor mutational burden (bTMB) on advanced NSCLC in Southwest China. The relationship between the tTMB estimated by next-generation sequencing (NGS) and clinical outcome was retrospectively analyzed in tissue specimens from 21 patients with advanced NSCLC. Furthermore, the relationship between the bTMB estimated by NGS and clinical outcome was retrospectively assessed in blood specimens from 70 patients with advanced NSCLC. Finally, 13 advanced NSCLC patients were used to evaluate the utility of bTMB assessed by NGS in differentiating patients who would benefit from immunotherapy. In the tTMB group, tTMB ≥ 10 mutations/Mb was related to inferior progression-free survival (PFS) (hazard ratio [HR], 0.30; 95% CI, 0.08-1.17; log-rank P = 0.03) and overall survival (OS) (HR, 0.30; 95% CI, 0.08-1.16; log-rank P = 0.03). In the bTMB group, bTMB ≥ 6 mutations/Mb was associated with inferior PFS (HR, 0.32; 95% CI, 0.14-1.35; log-rank P < 0.01) and OS (HR, 0.31; 95% CI, 0.14-0.7; log-rank P < 0.01). In the immunotherapy section, bTMB ≥ 6 mutations/Mb was related to superior PFS (HR, 0.32; 95% CI, 0.14-1.35; log-rank P < 0.01) and objective response rates (ORRs) (bTMB < 6: 14.2%; 95% CI, 0.03-1.19; bTMB ≥ 6: 83.3%; 95% CI, 0.91-37.08; P = 0.02). These findings suggest that bTMB is a validated predictive biomarker for determining the clinical outcome of advanced NSCLC patients and may serve as a feasible predictor of the clinical benefit of immunotherapies (anti-PD-1 antibody) in the advanced NSCLC population in Yunnan Province.